-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4498 Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Monday, December 9, 2024, 6:00 PM-8:00 PM

Konstantinos Christofyllakis1*, Igor Age Kos, MD1*, Bettina Altmann, PhD2*, Viola Poeschel, MD1*, Stephanie Maurer, MSc1*, Vadim Lesan1*, Jörg-Thomas Bittenbring, MD1*, Dominic Kaddu-Mulindwa, MD1*, Zanir Abdi1*, Manfred Ahlgrimm, MD3*, Sarah Altmeyer, MD1*, Octavian Fleser, MD1*, Gerhard Held, MD4*, Maike Nickelsen, MD5*, Martin Dreyling, MD6, Florian Zettl, MD7*, Christian Buske, MD8, Georg Lenz9, Bertram Glass, MD10*, Björn Chapuy11, Norbert Schmitz, MD9*, German Ott, MD12*, Reiner Siebert, PhD13*, Andreas Viardot, MD, PhD14, Florian Scherer, MD15, Roland Schmitz, PhD16*, Andreas Rosenwald, MD17*, Dirk Hellwig, MD18*, Nina Neuendorff, MD19*, Theodoros Vassilakopoulos20*, Chrysoula Doxani, MD, MSc21*, Pascal Blatt, MD22*, Oguzhan Nakisli1*, Susanne Schmidt, MD1*, Tobias Gaska, MD23, Börge Arndt, MD24*, Matthias Mueller, MD25*, Hanno Maximilian Witte, MD25*, Martin Bentz, MD26*, Volkmar Boehme, MD5*, Heinz Kirchen, MD23*, Markus Loeffler, MD2*, Boris Kubuschock, MD27*, Niklas Gebauer28*, Rolf Mahlberg, MD29*, Julian Topaly, MD30*, Alexander Bott, MD31*, Kai Wille, MD32*, Ralf Ulrich Trappe, MD33*, Mathias J. Rummel, MD34*, Gerald Illerhaus, MD35, Franziska Brunner, MD36*, Martin Klump, MD37*, Ulrich Kaiser, MD38*, Swen Wessendorf, MD39*, Iordanis Deligiannis, MD23*, Bert Hildebrandt, MD40*, Alexander Kiani, MD41*, Thomas Illmer, MD42*, Gabriele Prange-Krex, MD43*, Kristina Lerch, MD44*, Matthias Sandmann, MD45*, Sebastian Broeckling, MD46*, Uwe Martens, MD47*, Bastian von Tresckow48,49, Annkristin Heine, MD50*, Holger F. Hebart, MD51, Stephan Stilgenbauer, MD52,53, Lorenz Thurner, MD1, Moritz Bewarder, MD1* and Marita Ziepert, PhD2*

1Department of Oncology, Hematology, Clinical Immunology and Rheumatology, Saarland University Medical Center, Homburg/Saar, Germany
2Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany
3Department of Oncology, Hematology, Clinical, and Rheumatology, Saarland University Medical Center, Homburg/Saar, Germany
4Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern, Germany
5Oncology Lerchenfeld, Hamburg, Germany
6Department of Internal Medicine III, Ludwig-Maximilian-University Munich, Munich, Germany
7Department of Hematology and Oncology, Klinikum Traunstein, Traunstein, Germany
8Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
9Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
10Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany
11Department of Hematology, Oncology and Cancer Immunology, Charité - University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany
12Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
13Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany
14Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
15Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
16Institute for Pathology, Molecular Cytology and Functional Genomics, University Hospital Giessen, Giessen, Germany
17Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
18Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany
19Marien Hospital Herne-Universitätsklinikum der Ruhr-Universität Bochum, Herne, Germany
20Department of Hematology and Bone Marrow transplantation Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
21Laboratory of Biomathematics, Department of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
22Department of Oncology, Hematology, Clinical Immunology and Rheumatology, Saarland Universtity Medical Center, Homburg/Saar, Germany
23Department Internal Medicine I, Krankenhaus der Barmherzigen Brüder, Trier, Germany
24Department of Hematology and Oncology, Helios Klinikum Emil von Behring, Berlin, Germany
25Department of Hematology and Oncology, Bundeswehr Krankenhaus Ulm, Ulm, Germany
26Department Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
27Department of Internal Medicine II, Augsburg University Medical Center and Comprehensive Cancer Center Augsburg, CCC Alliance WERA and Bavarian Cancer Research Center (BZKF), Augsburg, Germany
28Department for Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
29Internal Medicine I, Hospital Mutterhaus der Borromäerinnen, Trier, Germany, Trier, DEU
30Department of Hematology and Oncology, Caritas Klinikum Saarbrücken, Saarbruecken, Germany
31Department of Internal Medicine V, Klinikum Nürnberg-Nord, Nuernberg, Germany
32University of Bochum, University Clinic For Hematology and Oncology Minden, Bochum, Germany
33Department of Internal Medicine III, DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany
34Department of Haematology-Oncology, Giessen University Hospital, Giessen, Germany
35Department of Hematology, Oncology, Stem-Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany
36Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany
37Department of Hematology and Oncology, Diakonie Klinikum Jung-Stilling, Siegen, Germany
3836. Department of Hematology, Immunology and medical Oncology, St. Bernward Krankenhaus, Hildesheim, Germany
39Cancer Center Esslingen, Klinikum Esslingen, Esslingen, Germany
40Department of Internal Medicine I, Werner Forßmann Hospital, Eberswalde, Germany
41Department of Hematology and Oncology, Klinikum Bayreuth, Bayreuth, Germany
42Hematology Private Practice, Dresden, Germany
43Gemeinschaftspraxis Dr. med. Johannes Mohm, Dr. med. Gabriele Prange-Krex Dresden, Dresden, Germany
44Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany
45Department of Internal Medicine III, Petrus-Krankenhaus, Wuppertal, Germany
46Department of Internal Medicine VI, Mathias Hospital Rheine, Rheine, Germany
47Hematology, Oncology, Palliative Care, SLK Clinic Heilbronn, Heilbronn, Germany
48Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
49Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
50Department of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Bonn, Germany
51Department of Internal Medicine, Hematology and Oncology, Stauferklinikum, Mutlangen, Mutlangen, Germany
52Comprehensive Cancer Center Ulm, University of Ulm, Ulm, Germany
53Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity and has increased incidence in the elderly. Approximately 40% of pts with DLBCL are >70 yrs old. In older/frail pts with untreated DLBCL, the attenuated chemotherapy regimen R-miniCHOP is the standard of care with a 2-yr overall survival (OS) of approximately 60% (Peyrade 2011). BTK inhibition added to R-CHOP improved OS in pts <60 yrs, but not in older pts where tolerability was limited (Younes 2019). A BTK inhibitor with a more favorable safety profile may improve survival also in elderly pts. Acalabrutinib is a second-generation BTK-inhibitor with promising data in combination with R-CHOP in pts with DLBCL up to 80 yrs (Davies ASH 2022). ARCHED/GLA 2022-1 is an investigator-initiated, randomized, open-label, phase 3 trial to evaluate the addition of acalabrutinib to R-miniCHOP in pts with untreated DLBCL aged >80 yrs or 61-80 yrs old and unfit for full-dose R-CHOP. Patients are randomized to receive either R-miniCHOP (control, C) or R-miniCHOP + Acalabrutinib (A). Stratification is based on age, ADL score and IPI. The primary endpoint is progression free survival.

Methods

This is a safety analysis based on the per protocol quarterly evaluation of serious adverse events (SAE) of the first year of recruitment. Recruitment started in June 2023. All pts randomized until 01/07/2024 were included. Baseline characteristics, SAE incidence and severity were analyzed. Adverse events of special interest (AESI) were reported as SAE.

Results

At data cut off 57 pts had been randomized (C: 28, A: 29). Median age was 83 yrs (range 66-94), 68% pts were >80 yrs old and 63% male. ECOG status was 0-1 in 67% and ADL score <6 in 28%. Extranodal disease was present in 77%, and 72% had an IPI score ≥3. Baseline characteristics were balanced between arms.

A total of 44 SAE were reported in 29 pts (C: 18 events [13 pts; 46%]; A: 26 events [16 pts; 55%]). Fifteen (34%) of them were grade 1-2 (C: 6 events [5 pts; 18%]; A: 9 events [5 pts; 17%]). Twenty (45%) were grade 3 (C: 7 events [6 pts; 21%]; A: 13 events [9 pts; 31%]). One pt in arm C and one in arm A had one grade 4 SAE each. Four deaths (grade 5 SAE) occurred in arm C (14%, one lymphoma-related, one heart failure and two unknown cause) vs three (10%, one due to vascular causes and two unknown cause) in arm A.

The most common SAE were infections. In arm C, 4 pts (14%) had one grade 2 and four grade 3 infections, and 5 pts (17%) in arm A had one grade 2 and five grade 3 infections. Cardiac events accounted for 10 SAE. Specifically, in two pts (7%) in arm C one heart failure grade 5, one grade 2 and one grade 3 hypertensive crisis occurred. Six pts (20%) in arm A had five grade 1-2 (three asymptomatic ventricular extrasystoles [AESI], one asymptomatic non-sustained ventricular tachycardia [AESI], and one angina pectoris) and two grade 3 (one atrial fibrillation and one heart failure). Three pts had bleeding SAE, two in arm C (hemoptysis and melena, both grade 1) and one in arm A (grade 3 rectal bleeding).

Conclusion

Acalabrutinib with R-miniCHOP resulted in increased but manageable toxicity. Rates of serious infections and bleeding were similar between groups. One third of all SAE reported were grade 1-2. More cardiologic SAE were reported in the experimental arm, mostly asymptomatic grade 1-2 AESI. Importantly, no increased rate of treatment emergent deaths was seen with acalabrutinib + R-miniCHOP in this frail, high-risk population. Thus, acalabrutinib with R-miniCHOP has the potential to improve outcomes in older/frail adults with untreated DLBCL.

ARCHED is an academic study of the German Lymphoma Alliance and is funded by AstraZeneca GmbH. The trial is approved in the EU and is recruiting in Germany. (EU-CTN: 2022-501187-18-00, NCT05820841).

Disclosures: Christofyllakis: Abbvie: Consultancy, Honoraria, Other: Travel grant; AstraZeneca: Consultancy, Honoraria, Other: Travel grant, Research Funding; Beigene: Consultancy, Other: Travel grant; Celgene: Other: Travel grant; Jazz Pharmaceuticals: Other: Travel grant; Hexal: Other: Travel grant; Novartis: Consultancy, Other: Travel grant; Kite/Gilead: Consultancy, Other: Travel grant; Takeda: Consultancy, Honoraria; Roche: Honoraria. Age Kos: Pfizer: Other: Travel funds. Poeschel: Swedish Orphan Biovitrum GmbH: Membership on an entity's Board of Directors or advisory committees; PentixaPharm GmbH: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: travel expenses, congress support; Abbvie: Other: travel expenses, congress support; Genmab: Other: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, congress support; Janssen-Cilag: Consultancy; AstraZeneca: Honoraria; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, congress support; EUSA Pharma: Consultancy; BeiGene: Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, congress support; Lilly: Membership on an entity's Board of Directors or advisory committees. Lesan: Pierre Fabre: Other: Travel and Congress Grant. Held: Abbvie: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Nickelsen: BMS: Honoraria; Incyte: Consultancy, Honoraria; AbbVie: Honoraria; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Takeda: Consultancy; Lilly: Consultancy, Honoraria; Sobi: Consultancy, Honoraria; AMGEN: Honoraria. Dreyling: AbbVie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Lilly, F. Hoffmann-La Roche Ltd.: Research Funding; AstraZeneca, Beigene, Gilead/Kite, Janssen, Lilly, Novartis, F. Hoffmann-La Roche Ltd.: Honoraria; AbbVie, AstraZeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Lilly/Loxo, Novartis, F. Hoffmann-La Roche Ltd.: Membership on an entity's Board of Directors or advisory committees. Zettl: AMGEN: Patents & Royalties: transfer agreement. Buske: AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; BeiGene: Consultancy, Honoraria, Speakers Bureau; MorphoSys: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead Sciences: Consultancy, Honoraria, Speakers Bureau; Celltrion: Consultancy, Honoraria, Research Funding, Speakers Bureau; Regeneron: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy, Honoraria, Speakers Bureau; Lilly: Consultancy, Honoraria, Speakers Bureau; MSD: Research Funding; Roche/Genentech: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Research Funding. Lenz: PentixaPharm: Honoraria; Pierre Fabre: Honoraria; Sobi: Honoraria, Speakers Bureau; Acerta: Research Funding; MSD: Honoraria; Genase: Honoraria; Genmab: Honoraria; Hexal/Sandoz: Honoraria; Immagene: Honoraria; Incyte: Honoraria; Karyopharm: Honoraria; Lilly: Honoraria; Miltenyi Biotech: Honoraria; NanoString: Honoraria; Janssen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche, Gilead, BMS, Novartis, AstraZeneca, Abbvie, Incyte, Genmab, Constellation, ADC Therapeutics, Miltenyi, PentixaPharm, Sobi, Immagene, Genase, Hexal-Sandoz, Lilly, Beigene, MSD, Pierre Fabre: Consultancy; ELVESCA: Current equity holder in private company; Roche, Gilead, BMS, Novartis, AstraZeneca, Abbvie, Incyte, Genmab, Constellation, ADC Therapeutics, Miltenyi, PentixaPharm, Sobi, Immagene, Genase, Hexal-Sandoz, Lilly, Beigene, MSD, Pierre Fabre: Membership on an entity's Board of Directors or advisory committees; AbbVie, BeiGene, Sobi, Roche, Gilead, BMS: Other: Travel; Constellation: Honoraria; BMS: Honoraria; BeiGene: Honoraria; Amgen: Honoraria; AbbVie: Honoraria; ADC Therapeutics: Honoraria; Verastem: Research Funding; Roche: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; MorphoSys: Honoraria, Research Funding; AGIOS: Research Funding; AstraZeneca: Honoraria, Research Funding; AQUINOX: Research Funding; Bayer: Honoraria, Research Funding; Gilead: Honoraria, Research Funding. Glass: Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Consultancy; Abbvie: Consultancy; Sobie: Consultancy; JAZZ: Honoraria. Chapuy: AbbVie, Bristol Myers Squibb, Incyte, Janssen, Roche, and Sobi: Consultancy; Sobi, Roche: Other: travel support ; AbbVie, Ars tempi, Astra Zeneca, BMS, Incyte, Janssen, Gilead, KML, Roche, Sobi, Ono: Honoraria. Schmitz: Astra Zeneca: Research Funding; Roche: Honoraria, Other: travel grant; Beigene: Other: travel grant; Abbvie: Research Funding; Janssen: Research Funding; BMS: Current equity holder in publicly-traded company. Viardot: AbbVie, Amgen, Kite, Roche, Astra Zeneca: Membership on an entity's Board of Directors or advisory committees; AbbVie, BMS, Kite, Novartis, Roche, Sobi: Honoraria. Scherer: Gilead Sciences: Research Funding; Takeda: Research Funding; AstraZeneca: Honoraria; Servier: Honoraria; Roche Sequencing Solutions: Research Funding. Neuendorff: Pfizer: Consultancy; Hexal: Consultancy. Schmidt: Johnson & Johnson: Other: Travel grant. Boehme: Roche: Consultancy, Honoraria, Speakers Bureau; Janssen-Cilag: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau; Gilead Sciences, Inc: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria, Speakers Bureau. Gebauer: Janssen: Honoraria, Other: travel support; Takeda: Honoraria; AstraZeneca: Honoraria; Menarini Stemline: Honoraria; Beigene: Honoraria, Other: travel support . von Tresckow: AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis: Other: Travel and congress support ; Allogene, Amgen, BMS/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Sobi and Takeda: Consultancy; AbbVie, AstraZeneca, BMS/Celgene, Gilead Kite, Incyte, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Roche and Takeda: Honoraria; Esteve (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), and Takeda (Inst): Research Funding. Heine: Astra Zeneca, AbbVie, Roche, Janssen, Lilly, Beigene, Novartis, Incyte, BMS: Consultancy, Other: travel expenses. Hebart: AbbVie, AstraZeneca, Beigene, Janssen: Consultancy. Stilgenbauer: Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Hoffmann-La Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; GSK: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Galapagos: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; BeiGene: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Lilly: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Sunesis: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau. Bewarder: AstraZeneca: Consultancy; Incyte: Honoraria; Janssen Pharmaceuticals: Consultancy, Honoraria.

OffLabel Disclosure: Acalabrutinib is currently not approved for the treatment of patients with DLBCL

*signifies non-member of ASH